Subtotal $0.00
Cagrilintide is a synthetic peptide developed by Novo Nordisk. It is a long-acting analog of amylin, a hormone that the pancreas releases together with insulin after meals. Amylin plays a role in signaling fullness and in slowing how quickly the stomach empties.
Cagrilintide was modified with a fatty acid chain so that it lasts much longer in the body than natural amylin.
Cagrilintide has been studied in clinical trials for weight management, both on its own and in combination with semaglutide. The combination is known as CagriSema and has its own profile in our Peptide Guide.
Another amylin analog, pramlintide, is already FDA-approved for use by certain people with diabetes who also use mealtime insulin. That approval does not apply to cagrilintide, which is a separate molecule.
Current status: Investigational – not FDA-approved.
Investigational means cagrilintide has been tested in clinical research but has not been approved by the FDA. It is not available as a prescription medicine in the United States.
The status of investigational drugs can change as trials finish and applications are reviewed. The FDA and ClinicalTrials.gov are the most reliable places to check where cagrilintide stands today.
Until the FDA approves it, any product sold as cagrilintide outside a clinical trial is not an approved medicine.
Peptide Labs does not sell this compound. This page is general information, not medical advice. Our Peptide Guide exists to explain what these compounds are and how they are regulated, not to supply them.
Anyone with questions about cagrilintide should speak with a licensed healthcare provider, who can explain the current evidence and the legal status in plain terms.
See the full list of compound profiles in the Peptide Guide. For background on what the label “FDA-approved prescription drug” means, read what "FDA-approved prescription drug" means.
Shop Now
